Physician profile
Bernard M Gerber
NPI 1588616254
$5,035.16
in general payments reported to CMS, 2019-2025
28 companies · $747 in 2025
The $747 reported for 2025 was more than what 77% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,953 · 2020: $424 · 2021: $264 · 2022: $274 · 2023: $730 · 2024: $642 · 2025: $747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,119.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $610.20 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $493.66 | 2019-2025 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $411.56 | 2021-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $378.14 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $374.37 | 2019-2025 | Spravato, Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $368.29 | 2019-2025 | Trintellix |
| Lundbeck LLC | $299.52 | 2019-2025 | Rexulti |
| Bausch Health US, LLC | $274.12 | 2019-2025 | Aplenzin, Wellbutrin |
| Neurocrine Biosciences, INC. | $267.00 | 2019-2025 | Ingrezza |
| Allergan, INC. | $210.42 | 2019-2020 | |
| Axsome Therapeutics, INC. | $154.65 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $139.15 | 2019-2024 | Fanapt |
| Shire North American Group INC | $135.17 | 2019 | |
| Ironshore Pharmaceuticals INC. | $119.31 | 2019-2023 | Jornay Pm |
| Corium, LLC | $113.82 | 2023-2025 | Azstarys |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $102.79 | 2019-2025 | Austedo Xr, Austedo Xr |
| Alkermes, INC. | $94.86 | 2019-2023 | Aristada, Lybalvi |
| Avanir Pharmaceuticals, INC. | $82.19 | 2019-2021 | |
| Tris Pharma INC | $75.87 | 2019-2025 | Dyanavel Xr |
| Neos Therapeutics, LP | $70.40 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $67.07 | 2019-2020 | |
| Adlon Therapeutics L.P. | $60.78 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $28.89 | 2023-2024 | Quviviq |
| Rhodes Pharmaceuticals L.P. | $24.86 | 2019 | |
| Mdd US Operations, LLC | $23.65 | 2019 | |
| Noven Therapeutics, LLC | $21.71 | 2021 | |
| Neuronetics, INC. | $17.29 | 2020 | |
| Arbor Pharmaceuticals, INC. | $15.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Gerber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.